Skip to main content

ASCPT 2025 Annual Meeting Main banner

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#

D
PII-044
DEMOGRAPHICS AND UTILIZATION OF MEDICATIONS WITH PHARMACOGENETICS GUIDELINES IN THE TRIAL OF PREMPTIVE PHARMAGOGENETICS IN UNDERSERVED PATIENTS (TOPP UP)

Favorite
PT-002
DETERMINING CRITICAL PHYSIOLOGICAL AND DRUG SPECIFIC PARAMETERS FOR ENHANCING A PHYSIOLOGICALLY-BASED PHARMACOKINETICS MODEL FOR THE FEMALE REPRODUCTIVE TRACT

Favorite
PWI-001
DETERMINING CRITICAL PHYSIOLOGICAL AND DRUG SPECIFIC PARAMETERS FOR ENHANCING A PHYSIOLOGICALLY-BASED PHARMACOKINETICS MODEL FOR THE FEMALE REPRODUCTIVE TRACT

Favorite
PT-011
DEVELOPING A SIMULTANEOUS PLASMA AND CENTRAL NERVOUS SYSTEM POPULATION PHARMACOKINETIC MODEL FOR DOLUTEGRAVIR EXPOSURE

Favorite
PT-023
DEVELOPMENT OF AN ADVANCED PBPK MODEL OF THE RESPIRATORY TRACT TO OPTIMIZE PULMONARY DELIVERY AND DOSING OF MO-OH-NAP TROPOLONE NANO-FORMULATION.

Favorite
PII-096
DEVELOPMENT OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO PREDICT PHARMACOKINETICS AND DRUG-DRUG INTERACTIONS FOR REPOTRECTINIB

Favorite
PI-111
DEVELOPMENT OF A QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL TO CHARACTERIZE THE EFFECTS OF INHALED CORTICOSTEROIDS ON PEDIATRIC BONE HEALTH.

Favorite
PII-126
DEVELOPMENT OF A SKIN DRYNESS PREDICTION MODEL BASED ON FACIAL IMAGES USING DEEP LEARNING: A PROSPECTIVE COHORT STUDY.

Favorite
PWII-002
DEVELOPMENT OF ADEFOVIR PBPK MODEL TO SUPPORT PROSPECTIVE EVALUATION OF BIOMARKER-INFORMED OAT1 INHIBITION AND EFFECT OF RENAL IMPAIRMENT

Favorite
PT-016
DEVELOPMENT OF ADEFOVIR PBPK MODEL TO SUPPORT PROSPECTIVE EVALUATION OF BIOMARKER-INFORMED OAT1 INHIBITION AND EFFECT OF RENAL IMPAIRMENT

Favorite
LB-020
DEVELOPMENT OF AN R SHINY APPLICATION TO STREAMLINE DRUG-DRUG INTERACTION SIMULATIONS UTILIZING THE SIMCYP-R PACKAGE.

Favorite
PII-116
DEVELOPMENT OF CHARACTERIZATION OF A TRANSDERMAL DRUG DELIVERY SYSTEM FOR ALZHEIMER'S DRUGS.

Favorite
PI-117
DEVELOPMENT OF POPULATION PHARMACOKINETICS MODEL AND R-SHINY SIMULATION PLATFORM FOR MOXIFLOXACIN IN NON-HUMAN PRIMATES

Favorite
E-004
DEVELOPMENT OF QSP PLATFORM MODEL FOR PREDICTING CLINICAL EFFICACY AND CRS INCIDENCE OF CD3 BISPECIFICS IN STEAP1 PROSTATE CANCER

Favorite
PI-004
DIGITAL HEALTH BIOMARKERS FOR CHARACTERIZING DEPRESSION SEVERITY TRAJECTORIES DURING ANTIDEPRESSANT TREATMENT.

Favorite
PI-063
DISPOSITION OF BEXICASERIN TO ITS MAJOR METABOLITE, N-CARBAMOYL GLUCURONIDE (M20), IS NOT INFLUENCED BY GENETIC POLYMORPHIC METABOLISM

Favorite
PI-044
DISRUPTING THE PD-L1 AND PDS5B INTERACTION BY COMPOUNDS: A PROMISING THERAPEUTIC STRATEGY FOR TRIPLE-NEGATIVE BREAST CANCER.

Favorite
TIP-001
DIVERSITY IN ACTION, CASE STUDIES OF ASTRAZENECA-SPONSORED PHASE-I TRIALS.

Favorite
PII-045
DNA METHYLTRANSFERASE INHIBITORS REDUCE TRIPLE NEGATIVE BREAST CANCER CELL GROWTH THROUGH ENHANCED IMMUNE RESPONSE BY DOWNREGULATION OF ZNF101

Favorite
PII-117
DRUG DEVELOPMENT CONSIDERATIONS FOR DRUG-DRUG INTERACTION STUDIES WITH FLUCONAZOLE AS A SIMULTANEOUS INHIBITOR OF MULTIPLE METABOLIC ENZYMES.

Favorite
PII-064
DRUG-DRUG INTERACTION MODEL DESCRIBES HIGH-DOSE METHOTREXATE PHARMACOKINETICS AFTER GLUCARPIDASE RESCUE

Favorite
PI-064
DRUG-DRUG INTERACTIONS BETWEEN ANDROGEN RECEPTOR SIGNALING INHIBITORS AND DIRECT-ACTING ORAL ANTICOAGULANTS IN PATIENTS WITH PROSTATE CANCER: LIMITED AGREEMENT BETWEEN VARIOUS DRUG-DRUG INTERACTION INFORMATION SOURCES

Favorite
PII-065
DRUG-DRUG INTERACTIONS BETWEEN LETERMOVIR AND TARGETED THERAPIES FOR GRAFT VERSUS HOST DISEASE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: HOW DO DRUG-DRUG INTERACTION CHECKERS COMPARE?

Favorite
PI-118
DRUG-INDUCED ADE PREDICTION MODEL PERFORMANCE DEPENDS ON STATISTICAL MODELS AND STATISTICALLY SIGNIFICANT THRESHOLDS FOR DRUG-INDUCED ADE DATA

Favorite